Each year we select our most exciting scientific discoveries to showcase our world-class cancer research.
We've selected a range of discoveries from 2022/2023 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
We've selected a range of discoveries from 2021/2022 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
We've selected a range of discoveries from 2020/2021 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
We've selected a range of discoveries from 2019/20 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
We're highlighting a range of discoveries from 2018/19. They were chosen because they illustrate the breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
We've selected a range of discoveries from 2017/18 – chosen because they illustrate the breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
Our top 10 discoveries of 2016/17 have been chosen because they display the range of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
We've selected our top 10 discoveries of 2015/16 – chosen because they illustrate the breadth of our basic, translational and clinical research and our ambitions under the new research strategy.
A genetic map of prostate cancer mutations is created, a new family of melanoma drugs discovered and the first clinical trial to demonstrate the benefits of viral immunotherapy is announced.
The structure of a critical protein for cell division is imaged, enzalutamide improves patient survival in men with prostate cancer before chemotherapy, and a genetic flaw links childhood brain cancer to stone man syndrome.
Pinpointing the first founder mutations that lead to leukaemia, using virtual experiments to uncover missing cancer targets, and discovering an intriguing gene link to breast and ovarian cancer.
Contact us to find out more about the ICR.